Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL
A Phase III, multi-center randomized, 24 week, double-blind, parallel group, placebo controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period
The purpose of this research study is to investigate if an experimental drug, R04917838, is effective at reducing negative symptoms of schizophrenia when added to your current antipsychotic treatment.
Please contact Alexian Brothers for more information on participation.
Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these